Additionally, emerging therapies targeting inflammation and fibrosis—such as anti-TGF-β1 antibodies—are being explored as adjunctive approaches to address the downstream effects of ERS in cardiomyopathies. The gene discussed is TGFB1; the disease is cardiomyopathy.